Product/Composition:- | Pegylated Interferon Alpha-1a |
---|---|
Strength:- | 120 mcg, 150 mcg, 180 mcg |
Form:- | Injection |
Reference Brands:- | Pegasys® (US & EU), PegIntron® (EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
PegIntron® is a pegylated interferon alpha-2b injection used to treat chronic Hepatitis C. Available in 120, 150, and 180 mcg prefilled syringes, it’s given once weekly at 1.5 mcg/kg subcutaneously. Often combined with ribavirin, PegIntron® is manufactured to EU-GMP and USFDA standards, making it suitable for B2B supply, hospital tenders, and licensing in EU and US markets.
PegIntron® is a pegylated interferon alpha-2b injection used for treating chronic Hepatitis C infection. It delivers a sustained antiviral effect by stimulating the immune response against the virus. Available in prefilled syringes with strengths of 120 mcg, 150 mcg, and 180 mcg, PegIntron® is administered once weekly via subcutaneous injection, typically dosed at 1.5 mcg/kg. Often combined with ribavirin, it is manufactured under EU-GMP and USFDA standards. PegIntron® is widely used in hospital tenders, B2B supply, and licensing with comprehensive regulatory dossiers to support market entry in EU and US.